NEW FDA DRUG APPROVAL
Medicine: Evkeeza
Active ingredient: evinacumab
Indication: homozygous familial hypercholesterolemia
Mechanism: evinacumab blocks angiopoietin-like protein 3 (ANGPTL3) – allowing faster breakdown of fats that lead to high cholesterol.